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Abstract
Background: Hypermobile Ehlers-Danlos syndrome (hEDS), is probably the most common disease among heritable
connective tissue disorders. It affects women more than men and causes symptoms in multiple organs. It is
associated with chronic pain, skin fragility and abnormal bleeding. These characteristics may hamper reproductive
life. We conducted a study to evaluate the gynecologic and obstetric outcomes in women with hEDS. We also
explored a possible hormonal modulation of the hEDS symptoms. The gynecologic and obstetric history of 386
consecutive women diagnosed with hEDS was collected by a standardized questionnaire and a medical
consultation performed by a senior gynecologist in an expert centre for hEDS between May 2012 and December
2014.
Results: We observed a high frequency of gynecologic complaints, specifically: menorrhagia (76 %), dysmenorrhea
(72 %) and dyspareunia (43 %). Endometriosis was not highly prevalent in this population. The obstetric outcomes
were similar to those of the general French population for deliveries by cesarean section (14.6 %) and premature
births (6.2 %) but the incidence of multiple spontaneous abortion (13 %) and spontaneous abortion (28 %) were
significantly higher. A subset of women were sensitive to hormonal fluctuations with more severe symptoms
occurring during puberty, prior to menstruation, during the postpartum period as well as on oral contraception.
Conclusions: Increased awareness of the gynecological symptomatology in women with hEDS can help
discriminate between endometriosis and thus prevent useless, and potentially dangerous, surgery. This study also
suggests that hormonal modulation may be an appropriate treatment for a subset of women with hEDS.
Keywords: Ehlers-Danlos syndrome, Hypermobility type, Recurrent abortion, Endometriosis, Bleeding disorders,
Premature delivery
Background
Ehlers-Danlos syndromes (EDS) belong to heritable con-
nective tissue disorders. Geneticists (Villefranche 1997)
have categorized six major forms of EDS including the
classic type (I, II), hypermobility type (hEDS) (III) and
vascular type (IV) as being the most frequent clinical
presentations [1]. However, while the vascular or classical
types of EDS may be associated with genetic variations, the
diagnosis of hEDS is based solely on clinical criteria. hEDS
is classically defined on the basis of major criteria: a
Beighton score of ≥5/9, skin involvement (hyperextensibility
and/or smooth, velvety skin) and minor criteria: recurring
joint dislocations, chronic joint/limb pain and a positive
family history [1]. According to an international group of
experts, and because of overlapping symptoms, Join hyper-
mobile syndrome (JHS) and hEDS could be the same clin-
ical entity [2]. Recent studies suggest that patients with
hEDS can experience a large range of dysfunction and in
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addition to mobile, loose joints, chronic pain (musculoskel-
etal pain, headache/migraine) [3] and variable skin involve-
ment, also including dysautonomia, gastrointestinal
functional disorder, fibromyalgia, and chronic fatigue syn-
drome among others [4]. Furthermore, not only does the
clinical spectrum of the disease and its functional conse-
quences vary widely but there is also a wide inter- and
intra-familial variability in the severity of symptoms [5–8].
Its prevalence is classically estimated at 1 in 5000 [1]
but may be higher according to recent debate about the
overlap with JHS reaching 0.75–2 % [7]. hEDS affects
women more often than men [6,8].
Previous studies have found an increase in abnormal
bleeding, dyspareunia and dysmenorrhea in patients with
EDS [9–12]. Four studies have reported on the gynaecolo-
gic and obstetric outcomes in women with both JHS,
hEDS and other EDS types with some discrepancies on
the prevalence of gynecologic complaint, spontaneous
abortion and obstetrical outcomes [9–14]. This can be
due to pooling different types of EDS in the analysis and
getting the information through a self-declaring question-
naire. Indeed the last largest study published was based on
an email questionnaire with no clinical validation [14].
We were therefore interested in conducting a study to
evaluate the prevalence of gynecologic disorders and the
impact on obstetric outcome using a standardized ques-
tionnaire during a medical consultation taking advantage
of a large cohort of women with hEDS. Because of con-
troversial reports on the role of estrogen and progestins
in hyperlaxity we also thought it would be interesting to
explore whether hormonal factors play a role in the
fluctuating symptoms of hEDS [15] .
Methods
The aim of this cohort study was to describe the
gynecologic symptoms and the obstetric history of a series
of women with hEDS. We also explored whether hEDS
symptoms were sensitive to the hormonal environment.
1. Patients
hEDS is a clinical diagnosis with no confirmatory test
available. Hence, all women had been clinically assessed
at least once by a single national expert in hEDS
between May 2012 and December 2014 then hEDS
women were sent to a consultation in Gynecology and
included. All had been formally diagnosed as having
hEDS as previously published [16–18]. The diagnosis
was based on actual or previous hypermobility, joint
instability, chronic pain, skin abnormalities and several
other criteria as chronic fatigue, proprioceptive
disorders, dysautonomia, migraines, digestive disorders.
Almost all patients had a family history of hEDS with
variability in severity of clinical symptoms among
relatives.
2. Methods
A standardized original questionnaire was completed
during the patient consultation.
The questionnaire included questions about:
– hEDS symptoms, luxation, joint pain, fatigue,
headache/migraine and digestive disorders.
– Gynecologic symptomatology, throughout the
reproductive life and at the time the
questionnaire was administered, including
dysmenorrhea, metrorrhagia, menorrhagia
(menstruation > 7 days, or > 5 sanitary napkins/
day) and dyspareunia.
– Gestation and parity, pregnancy outcomes and
deliveries.
The influence of hormones was evaluated by asking
the women about changes in the severity of their
predominant hEDS symptoms (chronic pain and
fatigue) (worsening, no effect, or improvement)
during puberty, while taking hormonal
contraceptives, during pregnancy, the postpartum
period, and menopause.
A gynecologic examination was performed for each
patient by a senior gynecologist (A.G). In cases of a
clinical suspicion of endometriosis (dysmenorrhea,
deep dyspareunia, or pelvic nodules found during
physical examination) or severe menorrhagia/
dyspareunia, a pelvic sonogram and, if necessary,
magnetic resonance imaging (MRI) were performed
by an experienced radiologist.
In our cohort, hemostatic disorders were
systematically ruled out in women presenting with
menorrhagia or hemorrhagic disorders.
3. Statistical analyses
Statistical analysis used procedures available in SAS
software (SAS Institute, Inc., Cary, NC). The student
t-test and the χ2 test were used to assess the
differences in characteristics of women between two
hEDS groups (not influenced by menstruation and
influenced by menstruation). Data are given as
percentage, mean and standard deviation (SD).
A p value of 0.05 was taken to represent statistical
significance.
Results
Overall, 386 women were included for analysis. The general
characteristics of the population are described in Table 1.
The hEDS symptoms were predominantly luxation in
86 % of women, joint pain in 96 %, fatigue in 92 % and
digestive disorders in 90 %.
Bleeding disorders were the most prominent
gynecologic symptoms (Table 2). Menorrhagia was
reported by 76 % of the women with an incidence
which did not vary according to age in premeno-
pausal women (p = 0.9).
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Dysmenorrhea was present in 72.8 % of the women
(Table 2). The frequency of dysmenorrhea did not vary
significantly with age (81 % of the women under 20 years,
74 % of those between 30 and 40 years and 67 % of
those above 40 years; p = 0.1). Among the 369 women
who had experienced sexual intercourse, severe dyspar-
eunia was reported by 61 %.
Endometriosis was diagnosed in 6 % of the women.
This percentage includes patients with a history of
surgical procedures for suspicion of endometriosis and
those for whom a clinical examination and/or a pelvic
sonogram/MRI was performed.
Obstetric outcomes
In the study population, there were 747 pregnancies for
225 women. The average number of pregnancies per
woman was 2.3 ± 2.3, with the average number of deliver-
ies being 1.4 ± 1.4. Of these, 441 deliveries were achieved
in 196 women. Spontaneous abortions were frequent,
occurring in 28 % of pregnancies. Forty-five percent of the
women had experienced at least one abortion; recurrent
abortion (defined as ≥3 abortions with the same partner)
occurred in 13 % of the women. Recurrent abortions were
not consecutive, with live births occurring in most of the
women (87 %). Eighty-five percent of the recurrent abor-
tions occurred before the age of 40. The mean age for the
last abortion was 25.9+/−5.9 years.
The majority of the pregnancies followed a favourable
course with severe complications occurring in a limited
number of cases. Twenty-six of the deliveries (6.2 %)
were preterm (i.e., before 37 weeks of amenorrhea).
Despite increased bleeding symptoms in these patients,
only 4.8 % of the births were complicated with postpartum
haemorrhage. Similarly, despite skin fragility, only 2.4 % of
deliveries were complicated with severe vaginal tears.
Cesarean section was performed in 14.6 % of births.
Influence of reproductive life on hEDS
Out of 70.4 % of the women who had experienced symp-
toms of hEDS before the onset of puberty, 52 % associ-
ated puberty with a worsening of the symptoms. The
onset of hEDS symptoms coincided with puberty in
16.9 % of the cohort. Overall then, 51.5 % of the
population reported that puberty had a deleterious
influence: those for whom puberty was associated with a
worsening of the symptoms and those for whom puberty
marked the onset of symptoms.
In the whole cohort, 162 women (42 %) had used
combined hormonal contraceptives (CHC), for an
average duration of 8.8 ± 7.6 years. Progestin-only
contraceptives (POP) in the form of a low-dose mini pill
or antigonadotropic agents at higher doses had been
prescribed for medical indications (e.g., menorrhagia,
dysmenorrhea, benign uterine conditions or due to a
contraindication to CHC) in 67 women (17 %). An
improvement in hEDS symptoms was reported by
13.6 % of the women using CHC and 25.4 % of those
using POP, (p = 0.03) (OR, 0.46 [CI 95 %, 0.23–0.94]).
hEDS symptoms worsened for 26 % of the women during
pregnancy and for 37.6 % during the postpartum period.
Overall, 16.8 % of the women included in the study
were postmenopausal. Among these, 22 % reported an
improvement in their symptoms after menopause.
Menopausal hormone therapy (MHT) had been used by
41.5 % of these patients for a mean duration of 6.8 ±
5.5 years. Four of these patients observed an improve-
ment in their hEDS symptoms as a result of MHT.
Sub-analysis of the women who experienced cyclic effect
on chronic pain and fatigue
Over one-third of the women (n = 133) experienced a
worsening of symptoms during each perimenstrual period.
We carried out a sub-analysis of these women, to
determine whether they were also affected by puberty,
CHC or pregnancy compared to those women who
reported no cyclic influence (n = 197). There was no
difference among the two groups in terms of age at diag-
nosis, age at onset of symptoms, number of pregnancies
or CHC duration of use.
Seventy-eight (59 %) of the women reporting cyclic
variations (p = 0.01) (Table 3) reported that their symp-
toms began or worsened at puberty. CHC use was asso-
ciated with a significant worsening of symptoms among
Table 1 General characteristics of the hEDS population (n = 386)
Age at inclusion [mean (SD); in years] 37.8 (14.1)
Age at diagnosis [mean (SD); in years] 35.3 (14.2)
Age at first symptoms [mean (SD); in years] 12.5 (11.8)
Age at puberty [mean (SD); in years] 12.5 (1.7)
hEDS symptoms
Joint pain (%) 370 (96)
Fatigue (%) 353 (92)
Luxation (%) 333 (86)
Digestive disorders (%) 345 (90.1)
Migraine and headache (%) 289 (75.5)






Deep dyspareuniea 118 (38)
Intromission dyspareuniea 148 (43)
Endometriosis 20 (6)
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patients with menstrual aggravation. One-fourth of the
women whose symptoms were influenced by menstru-
ation stated that their symptoms were modified when
taking CHC, in contrast with only 5.6 % in the group
whose hEDS symptoms were uninfluenced (p = 0.001)
(Table 3). Furthermore, women experiencing cyclic mod-
ulations also experienced worsened symptoms during
the postpartum period (p = 0.05).
Discussion
This study describing the gynaecologic and obstetric
symptoms in a large cohort of women with hEDS
suggests that most women experience significant gynae-
cologic symptoms and that few severe complications
occur during pregnancy. In addition, this is the first
study to describe the impact of reproductive life on
hEDS clinical outcomes.
Abnormal bleeding, dysmenorrhea and dyspareunia
were the most common gynecologic complaints in our
hEDS population. Dysmenorrhea was not correlated
with age and did not improve after deliveries contrary to
what is observed with idiopathic dysmenorrhea [19]. A
recent comprehensive literature review reported that
severe dysmenorrhea affected between 2 and 29 % of
women and that dysmenorrhea was negatively associated
with women’s age and parity [20]. Easy bruising and
bleeding are frequently described in EDS, a result of
weakness in the capillaries and perivascular connective
tissue rather than from hemostatic dysfunction [11]. The
sexual life of these women is also adversely affected by a
high incidence of dyspareunia. Previous studies have also
found an increase in abnormal bleeding, dyspareunia
and dysmenorrhea in patients with EDS [9, 10, 13, 14].
The two last publications have selectively reported on
the gynaecologic and obstetric outcomes in patients with
hEDS/JHS. The first involved 82 women in Italy with 93
pregnancies [10] and the second study included about
770 women with both hypermobility type and other EDS
types as well based on an email questionnaire with no
clinical validation [9]. Both studies reported similar
prevalence of dysmenorrhea and dyspareunia in women
with hEDS/JHS than in our population. The combin-
ation of these symptoms is highly suggestive of
endometriosis. The rate of endometriosis we found was
the same as that for the general population (3–6 %) and
much less than in women with chronic pain [21]. While
it is possible that we underestimated the frequency of
endometriosis because we did not perform systematic
laparoscopy, we suggest that endometriosis may be over-
diagnosed in hEDS patients because of reports of
chronic pain and bleeding. A systematic study would
nevertheless be interesting to evaluate the prevalence of
adenomyosis at a young age in women with EDS as it
may play a role in the high risk of spontaneous abortion.
A previous study, which also used a questionnaire, found
a 15 % prevalence of reported endometriosis [9]. A 22 %
prevalence of endometriosis among women with
suspected infertility was reported by women with EDS
from an emailed questionnaire which did not allow to
validate the diagnosis of endometriosis. In our patient
population, the conception rate was close to that for
women in France in general (fertility rate: 1.8–2.03
between 1980 and 2013 [22]). This finding further
argues against the hypothesis of an abnormally high
prevalence of endometriosis in this population. However,
while the rate of conception in our population was similar
to the normal range, the rate of spontaneous abortions
was higher than in the general population (28 % versus
about 20 %, respectively). Furthermore, the rate of
multiple abortions was much higher in our population
than in the French population as a whole (13 % versus
about 1 %, respectively) [23]. The cause of the miscar-
riages is unclear. An increased contractility of the uterus
or a fragile cervix, related to the connective tissue defect
and dysautonomic syndrome could be a cause [24]. An-
other possible explanation could be implantation defects.
One novel aspect of our study is the relationship
between hEDS symptoms and reproductive life. It is sig-
nificant that estradiol receptors are present in many of
the body structures and organs including joints, skin,
and cartilage. Puberty does appear to significantly ex-
acerbate symptoms. This may result either from the
rapid growth that is characteristic of this time in life —
and that significantly affects skin, joints and muscle-
s—and/or to the rapid increase in estrogen secretion. In
the subset of patients who deteriorate during the
Table 3 The influence of hormones on hEDS symptoms (hEDS symptoms: chronic pain, fatigue)
hEDS patients not influenced by menstruation
n = 197 (%)
hEDS patients influenced by menstruation
n = 133 (%)
p
Influenced by puberty 85/197 (43.2) 79/133 (58.7) 0.01
Impact of CHC
Worsened on CHC 5/90 (5.6) 15/58 (25.9) 0.001
Improved on CHC 12/90 (13.3) 9/58 (15.5)
Unchanged on CHC 73/90 (81.1) 34/58 (58.6)
Improved by menopause 6/33 (18.2) 3/17 (17.7) NS
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perimenstrual period, CHC was also correlated with an
increase in symptoms. Our analysis of contraception
suggests that, in some women at least, the hEDS symp-
toms responsible for increased disability might improve
with the use of POP. Our findings suggest that, when
menstrual disorders are treated and alleviated either by
CHC or by POP, EDS symptoms improve and women
report less fatigue. In the literature, there is conflicting
data as to the effects of hormones on connective tissue,
joint laxity and tendons. It has been demonstrated that
estradiol decreases the formation of collagen in tendons
following exercise [25]. Joint laxity increases during
pregnancy in some women. Another smaller study found
increased knee laxity during ovulation compared with the
luteal phase, but no significant changes during the phases
of the menstrual cycle [26]. A prospective trial would be
useful to determine the precise nature of the role of estro-
gens and progestins on various symptoms of hEDS.
This study also reveals that the prevalence of obstetric
complications is not substantially greater compared to
the healthy population and lower [27] in comparison
with the previously mentioned large, recently-published
study [14]. This discrepancy may result from the differ-
ent methodologies used in the two studies, or from a
difference in the protocols for management of pregnan-
cies from one country to another. Indeed, the Italian
study fitted more with our results with 10.7 % preterm
deliveries; we agree with these authors than caesarean
section is not indicated systematically in women with
hEDs and was performed only in 14 % of our patients.
Strengths and weaknesses of this study
Strengths
The cohort used in this study is quite large for a rare
disease. The standardized questionnaire was filled out
face to face with the patient; and the medical reports
were validated and corroborated by a medical
examination performed by a senior gynaecologist
trained in the diagnosis of endometriosis. This offers a
stronger basis for validation of symptoms than the
study carried out by Hurst et al.[14] in which
information was gathered via email.
Weaknesses
Much of the data was gathered from patients’
recollection of past events and the information is
therefore subject to recall bias. However, the
gynaecologic symptoms (menorrhagia, dysmenorrhea
and dyspareunia) persisted at the time of the
consultation and could be evaluated more accurately.
Conclusion
Women affected by hEDS present significant gynaecolo-
gic symptoms that are often are disabling, such as
menorrhagia, dysmenorrhea, deep and intromission dys-
pareunia. Endometriosis may be incorrectly diagnosed
on the basis of these symptoms, thereby leading to in-
appropriate treatment. The obstetric outcomes were
mostly reassuring in this population. Furthermore, hor-
mones may play a modulatory effect in this syndrome,
and their influence merits further study.
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